BRCA1 and neoplasm: Targeting BRCA1-mutated breast cancer by restoring its function through homologous recombination repair (HDR) in combination with PARP inhibitors induced tumor cell apoptosis up to 70% (Nesic et al., 2024), highlighting the therapeutic potential of precision editing for high-frequency driver mutations.